R&D Systems™ Recombinant Human BCMA/TNFRSF17 Fc Chimera Protein

Description

Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility. Applications: Bioactivity

The Recombinant Human BCMA/TNFRSF17 Fc Chimera Protein is derived from NS0. The Recombinant Human BCMA/TNFRSF17 Fc Chimera Protein has been validated for the following applications: Bioactivity.

Specifications

• Formulation: Lyophilized from a 0.2μm filtered solution in PBS.
• Gene ID (Entrez): 608
• Molecular Weight (g/mol): 32 kDa (monomer)
• Name: BCMA/TNFRSF17 Fc Chimera
• Quantity: 50 μg
• Source: Mouse myeloma cell line,NS0-derived human BCMA/TNFRSF17 protein, (N-terminus) Human BCMA (Met1-Ala54) Accession &Num; Q6PE46 IEGRMD Human IgG1 (Pro100-Lys330) (C-terminus)
• Storage Requirements: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70° C as supplied. 1 month, 2 to 8° C under sterile conditions after reconstitution. 3 months, -20 to -70° C under sterile conditions after reconstitution.
• Structural Form: Disulfide-linked homodimer
• Gene Alias: B cell maturation antigen, B-cell maturation protein, BCMAtumor necrosis factor receptor superfamily member 17, BCMB-cell maturation factor, CD269, CD269 antigen, TNFRSF13A, TNFRSF17, tumor necrosis factor receptor superfamily, member 17
• Conjugate: Unconjugated
• Recombinant: Recombinant
• Purity or Quality Grade: 95%, by SDS-PAGE under reducing conditions and visualized by silver stain.